We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Stellar's second patent issued as United States Patent No. 8,084,441, entitled "Cystitis Treatment with High Dose Chondroitin Sulfate," relates to the treatment of IC/PBS by instillation of an optimized unit dose of chondroitin sulfate that is at least 350mgs or more. The Company expects this patent to issue. Once issued, the patent will expire in 2023.

Rob Harris, Stellar's President and Chief Executive Officer, commented, "This second patent expands the scope of Stellar's exclusive rights in the United States for Uracyst, and further validates the innovative nature of Stellar's approach to the treatment of interstitial cystitis/painful bladder syndrome, and underscores the Company's position as a leader in this field". Mr. Harris went on to say that several companies have expressed an interest in the US rights to Uracyst.